8-K: C4 Therapeutics Director Bruce Downey Announces Retirement

Bruce Downey will retire from C4 Therapeutics' Board of Directors and not stand for reelection at the 2025 Annual Meeting of Stockholders.

Summary

• On April 10, 2025, Bruce Downey informed C4 Therapeutics' Board of Directors of his decision to retire.
• Downey will not seek reelection at the 2025 Annual Meeting of Stockholders.
• His decision was not due to any disagreements with the company regarding its strategy, operations, policies, or practices.
• Following the 2025 Annual Meeting, Downey will step down from his roles as director, chair and member of the Organization, Leadership and Compensation Committee, member of the Audit Committee, and member of the Nominating and Corporate Governance Committee.

Sentiment

Score: 6

Explanation: Neutral sentiment as it reports a routine director retirement with no indication of underlying issues.

Positives

• The company states that Bruce Downey's decision to retire was not due to any disagreements with the company on any matter relating to the company's strategy, operations, policies or practices.

Industry Context

Director retirements are a normal part of corporate governance. The key is whether the departure signals deeper issues within the company.

Management Changes

Stakeholder Impact

• Shareholders may be interested in who will replace Bruce Downey on the Board and committees.
• Employees may be affected by changes in committee leadership.

Next Steps

• The company will need to appoint a new chair and members for the Organization, Leadership and Compensation Committee, Audit Committee, and Nominating and Corporate Governance Committee.

Key Dates

Keywords

C4 Therapeutics, Board of Directors, Bruce Downey, Retirement, Director, Resignation, Governance